MedTrace Logo

YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

NCT01427582 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2011-09-01

No results posted yet for this study

Summary

The YONDELIS (trabectedin) Single Patient Compassionate Use /Expanded Access program provides patients with advanced soft tissue sarcoma, who do not qualify for ongoing clinical trials with YONDELIS (trabectedin), access to this investigational treatment.

Conditions

  • Soft Tissue Sarcoma

Interventions

DRUG

Trabectedin

Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • John C. Bagwell, MD · University of Texas

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01427582 on ClinicalTrials.gov